ReviewImmunity2015
Emerging functions of amphiregulin in orchestrating immunity, inflammation, and tissue repair.
Review in Immunity, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 398 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
398 citing papers in PubMed, 1 synthesis or guideline pooled it, 606 citations in OpenAlex.
- Dissecting the genetic and proteomic risk factors for delirium.Nature aging · 2026Pooled it
- Hormone therapy enhances anti-PD1 efficacy in premenopausal estrogen receptor-positive and HER2-negative advanced breast cancer.Cell reports. Medicine · 2025Trial
- Zinc silicate microspheres-mediated bacterial metabolic interference and microenvironment remodeling for chronic wound repair.Bioactive materials · 2027Article
- A tributyrin-monolaurin complex protects piglets against PEDV infection via viral inhibition, lipid metabolism restoration, and microbiota modulation.Animal nutrition (Zhongguo xu mu shou yi xue hui) · 2026Article
- Failed Mucosal Allostasis Distinguishes Murine IgG- From IgE-Mediated Recurrent Severe Anaphylaxis.Allergy · 2026Article
- Reverse-Engineered Lipid Nanoparticles Harness Protein Corona Formation for Cytokine Sequestration and Combination Immunomodulatory Therapy.Small (Weinheim an der Bergstrasse, Germany) · 2026Article
- Article
- Interleukin-33 and its receptor: multifaceted roles and emerging therapeutic potential.Nature reviews. Immunology · 2026Review
- Tissue-resident immune cells drive genetic risk in autoimmune and lung diseases.Nature immunology · 2026Article
- Single-cell landscape of human liver sinusoidal γδ T cells in the context of latent human cytomegalovirus infection.Nature communications · 2026Article
- Host-interferon-stimulated gene response to virus-host recombinant variants of hepatitis E virus and enhanced viral replication.Microbiology spectrum · 2026Article
- Review
- Rapid Human Skin Barrier Disruption by Sodium Dodecyl Sulfate and Associated Molecular Mechanisms.Allergy · 2026Article
- Immunoengineering External Field Responsive Biomaterials for Tissue Repair and Regeneration.Advanced materials (Deerfield Beach, Fla.) · 2026Review
- Functional Profile of γδ T Cells in Severe and Moderate COVID-19: A Brazilian Cross-Sectional Study.Cells · 2026Article
- Elevated ST2Arthritis research & therapy · 2026Article
- The Epidermal Growth Factor Receptor (EGFR) as a means of neuro-immune cross-conversation.Journal of neuroinflammation · 2026Review
- Article
- STAT1 expression in myeloid cells restrains murine norovirus-induced hepatitis and fibrosis.bioRxiv : the preprint server for biology · 2026Article
- ILC2s and their immune checkpoints in the antitumor response.Journal for immunotherapy of cancer · 2026Review
338 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
Abstract
Type 2 inflammatory responses can be elicited by diverse stimuli, including toxins, venoms, allergens, and infectious agents, and play critical roles in resistance and tolerance associated with infection, wound healing, tissue repair, and tumor development. Emerging data suggest that in addition to characteristic type 2-associated cytokines, the epidermal growth factor (EGF)-like molecule Amphiregulin (AREG) might be a critical component of type 2-mediated resistance and tolerance. Notably, numerous studies demonstrate that in addition to the established role of epithelial- and mesenchymal-derived AREG, multiple leukocyte populations including mast cells, basophils, group 2 innate lymphoid cells (ILC2s), and a subset of tissue-resident regulatory CD4(+) T cells can express AREG. In this review, we discuss recent advances in our understanding of the AREG-EGF receptor pathway and its involvement in infection and inflammation and propose a model for the function of this pathway in the context of resistance and tissue tolerance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.